🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Is lactate really a ’phoenix risen’ that drives numerous beneficial effects of exercise? Our new study in Nature Metabolism reveals major methodological flaws that affect studies of sodium lactate and potentially also other metabolite salts. Thread 👇 1/16 nature.com/articles/s4225…

Our latest research sheds light on the intricate cross talk between GLP-1 (liraglutide) and nicotine biology. As the clinical use of GLP-1 based drugs increases, understanding the interaction with nicotine/tobacco consumption becomes increasingly relevant cell.com/cell-reports/f…

A drug originally developed to treat #diabetes and severe overweight may also be able to help people with #nicotine dependence 💊🚫🚬 Read more about the discovery by the Christoffer Clemmensen Group, which was recently published in Cell Reports 👇 cbmr.ku.dk/news/2023/need…

The first Danish peptide symposium takes place in Copenhagen on August 31 eventsignup.ku.dk/danishpeptides…

Fascinating developments in weight loss drugs! Eli Lilly's triagonist phase 2 data: Nearly half of participants achieved >25% weight loss, with a quarter surpassing the impressive >30% mark. The bar continues to rise for incretin-based therapies. nejm.org/doi/full/10.10…

🏆 I am deeply honored to be one of the recipients of the UCPH: BII Life Science Innovation Award 2023 at the SUND Innovation Day 2023. It was truly exciting to showcase our innovative solutions that were born in the Christoffer Clemmensen lab and later incorporated to Ousia Pharma.

Exciting news! My main paper for my PhD in the Christoffer Clemmensen lab with Pablo Ranea-Robles is now published in @naturecomms! 🎉 It delves into how the body is naturally defended against excessive weight gain. A🧵👇#obesityresearch 1/11 nature.com/articles/s4146…

Insightful News and Views´ from Tyler Cook and Darleen Sandoval on our recent paper.

Research Highlight in Nature Reviews Drug Discovery covering our recent paper on targeted NMDA receptor antagonism for obesity treatment nature.com/articles/d4157…

Big day for the lab as our latest paper is out in Nature Chemical Biology Nature Chemical Biology on identifying the oxybipins as new OSBP inhibitors, as well as their mechanism of action and therapeutic applications! nature.com/articles/s4158… 1/n

A few months back, we published a study in Science Advances demonstrating the potential of targeting postsynaptic glutamate receptor scaffolding proteins, such as PSD-95, for sustained weight loss. Headed by Nicole Fadahunsi, Jonas Odgaard Petersen and Sophia Metz science.org/doi/10.1126/sc…

1/4 New paper out in Molecular Metabolism in which we show that calorie restriction before starting treatment with semaglutide or tirzepatide pushes maximum achievable weight loss by ~8% sciencedirect.com/science/articl…

Thrilled to have contributed to this snapshot article on "Brain-Targeting Anti-Obesity Medications" appearing today in Cell Metabolism on #WorldObesityDay.